Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive
This randomized phase III trial is studying fulvestrant and lapatinib to see how well they work compared to fulvestrant and a placebo in treating postmenopausal women with stage III or stage IV breast cancer that is hormone receptor-positive. Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant may fight breast cancer by lowering the amount of estrogen the body makes. Lapatinib may stop the growth of breast cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether fulvestrant is more effective with or without lapatinib in treating breast cancer.
Recurrent Breast Cancer
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Stage IV Breast Cancer
Drug: lapatinib ditosylate
Other: laboratory biomarker analysis
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||Endocrine Therapy With or Without Inhibition of EGF and HER2 Growth Factor Receptors: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib (GW572016) for Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer|
- Progression-free survival (PFS) [ Time Frame: Interval from randomization until disease progression or death, whichever occurs first, assessed up to 5 years ] [ Designated as safety issue: No ]One-sided O'Brien-Fleming boundaries will be used to stop for superiority. Futility boundaries will be based on testing the alternative hypothesis at a one-sided 0.005 alpha level, as recommended by Freidlin and Korn. Specifically, Z-score futility boundaries will be calculated as 2.576 + log(1.5)*sqrt (n/4), where n is the total number of observed events. The final analysis will use the stratified log-rank test to test for a difference between the treatment arms in PFS (one-sided alpha of 0.025) where the stratification factors are prior tamoxifen (yes/no) and bone-only disease (yes/no).
- Treatment-related toxicity as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 [ Time Frame: Day 1 of each course ] [ Designated as safety issue: Yes ]At each interim analysis the Fisher exact test or chi-square test, as appropriate, will be used with a one-sided Type I error rate of 5% to test arm differences in toxicity. We will also tabulate the frequency of treatment related toxicity by type, grade, and arm.
- Objective tumor response as defined by Response Evaluation Criteria in Solid Tumors (RECIST) for patients with measurable disease [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]The response rate of measurable tumors will be estimated with its 95% confidence interval according to treatment arm.
- Duration of tumor response [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]A Kaplan-Meier analysis will be used to compare the arms on response duration.
- Overall survival [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]The proportional hazards model to do a stratified analysis to compare the arms on overall survival will be used.
- Quality of life (QOL) as measured by the symptom assessment score using the Memorial Symptom Assessment Scale (C-991) [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
|Study Start Date:||September 2006|
|Primary Completion Date:||July 2014 (Final data collection date for primary outcome measure)|
Experimental: Arm I (enzyme inhibitor therapy, hormone therapy)
Patients receive oral lapatinib ditosylate once daily on days 1-28 and fulvestrant intramuscularly (IM) on days 1 and 15 of course 1 and on day 1 of each subsequent course.
Drug: lapatinib ditosylate
Other Names:Drug: fulvestrant
Other Names:Other: laboratory biomarker analysis
Placebo Comparator: Arm II (hormone therapy)
Patients receive oral placebo once daily on days 1-28 and fulvestrant as in arm I.
Other Names:Other: placebo
Other Name: PLCBOther: laboratory biomarker analysis
I. Compare the progression-free survival of postmenopausal women with stage III or IV hormone receptor-positive breast cancer treated with fulvestrant with or without lapatinib ditosylate.
I. Compare the response rate in patients treated with these regimens. II. Compare response and stable disease rate (i.e., complete response, partial response, and stable disease > 6 months) in patients treated with these regimens.
III. Compare the duration of response in patients treated with these regimens. IV. Compare the overall survival of patients treated with these regimens. V. Compare the quality of life of patients treated with these regimens. VI. Compare the toxicity of these regimens in these patients.
OUTLINE: This is a multicenter, open-label, randomized, double-blind, placebo-controlled study. Patients are stratified according to prior tamoxifen citrate therapy (yes vs no) and bone disease only (yes vs no). Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive oral lapatinib ditosylate once daily on days 1-28 and fulvestrant intramuscularly (IM) on days 1 and 15 of course 1 and on day 1 of each subsequent course.
ARM II: Patients receive oral placebo once daily on days 1-28 and fulvestrant as in arm I.
In both arms, treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and then on day 1 of every 2 courses of treatment (i.e., day 1 of courses 3, 5, 7, etc.).
After completion of study treatment, patients are followed every 6 months for 2 years and then annually for 3 years.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00390455
Show 268 Study Locations
|Principal Investigator:||Harold Burstein||Cancer and Leukemia Group B|